Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:ATYR NASDAQ:HYPD NASDAQ:KTTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.98-2.2%$4.67$2.66▼$7.00$44.16M0.2521,372 shs9,374 shsATYRaTyr Pharma$0.51-1.1%$0.52$0.40▼$7.29$49.99M0.522.34 million shs710,149 shsHYPDHyperion DeFi$2.74-0.4%$3.26$2.49▼$15.45$41.53M2.49402,741 shs295,800 shsKTTAPasithea Therapeutics$0.45-1.6%$0.60$0.28▼$2.06$11.22M0.291.61 million shs195,569 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-2.16%-8.29%-3.11%+11.41%+7.33%ATYRaTyr Pharma-1.14%-6.32%+10.17%-40.24%-91.27%HYPDHyperion DeFi-0.36%-11.33%-22.38%-38.57%-82.84%KTTAPasithea Therapeutics-1.57%-8.61%-10.41%-39.39%-35.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.98-2.2%$4.67$2.66▼$7.00$44.16M0.2521,372 shs9,374 shsATYRaTyr Pharma$0.51-1.1%$0.52$0.40▼$7.29$49.99M0.522.34 million shs710,149 shsHYPDHyperion DeFi$2.74-0.4%$3.26$2.49▼$15.45$41.53M2.49402,741 shs295,800 shsKTTAPasithea Therapeutics$0.45-1.6%$0.60$0.28▼$2.06$11.22M0.291.61 million shs195,569 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-2.16%-8.29%-3.11%+11.41%+7.33%ATYRaTyr Pharma-1.14%-6.32%+10.17%-40.24%-91.27%HYPDHyperion DeFi-0.36%-11.33%-22.38%-38.57%-82.84%KTTAPasithea Therapeutics-1.57%-8.61%-10.41%-39.39%-35.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.40Hold$13.00161.04% UpsideATYRaTyr Pharma 2.25Hold$17.003,233.33% UpsideHYPDHyperion DeFi 2.25Hold$6.95153.65% UpsideKTTAPasithea Therapeutics 2.00Hold$3.00566.67% UpsideCurrent Analyst Ratings BreakdownLatest KTTA, ATYR, HYPD, and ATHE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2026ATYRaTyr Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/14/2026HYPDHyperion DeFi Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/1/2026HYPDHyperion DeFi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $6.606/30/2026ATHEAlterity Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/26/2026ATYRaTyr Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/17/2026ATHEAlterity Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/16/2026ATHEAlterity Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.006/16/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.006/8/2026HYPDHyperion DeFi Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.25 ➝ $7.30(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/AATYRaTyr Pharma$190K263.19N/AN/A$0.69 per share0.74HYPDHyperion DeFi$810K51.28N/AN/A$4.73 per share0.58KTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$7.87MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)ATYRaTyr Pharma-$74.12M-$0.73N/AN/AN/AN/A-100.14%-73.55%8/6/2026 (Estimated)HYPDHyperion DeFi-$45.31M-$9.95N/A2.38N/AN/A-91.59%-73.08%N/AKTTAPasithea Therapeutics-$20.43M-$2.08N/AN/AN/AN/A-57.44%-53.61%8/13/2026 (Estimated)Latest KTTA, ATYR, HYPD, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026N/AKTTAPasithea Therapeutics-$0.16N/AN/AN/A$0.30 millionN/A8/6/2026Q2 2026ATYRaTyr Pharma-$0.15N/AN/AN/AN/AN/A5/15/2026Q1 2026ATYRaTyr Pharma-$0.16-$0.11+$0.05-$0.11N/AN/A5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AATYRaTyr PharmaN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A21.97N/AATYRaTyr PharmaN/A5.785.78HYPDHyperion DeFi0.121.971.97KTTAPasithea TherapeuticsN/A35.4135.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%ATYRaTyr Pharma61.72%HYPDHyperion DeFi25.84%KTTAPasithea Therapeutics23.92%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%ATYRaTyr Pharma5.75%HYPDHyperion DeFi7.50%KTTAPasithea Therapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableATYRaTyr Pharma5398.05 million92.41 millionOptionableHYPDHyperion DeFi4015.16 million14.02 millionNo DataKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionableKTTA, ATYR, HYPD, and ATHE HeadlinesRecent News About These CompaniesPasithea Therapeutics (NASDAQ:KTTA) Trading Down 1.6% - Here's What HappenedJuly 9, 2026 | americanbankingnews.comPasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision SummitJuly 8, 2026 | globenewswire.comPasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF ...June 30, 2026 | finance.yahoo.comPasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol ExpansionJune 30, 2026 | globenewswire.comPasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical TrialJune 16, 2026 | globenewswire.comPasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF ConferenceJune 15, 2026 | finance.yahoo.comPasithea Therapeutics to Engage with NF1 Community at 2026 Children's Tumor Foundation Conference Following FDA Designations for PAS-004June 15, 2026 | quiverquant.comQPasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF ConferenceJune 15, 2026 | globenewswire.comPasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock NowJune 10, 2026 | zacks.comPasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)June 2, 2026 | globenewswire.comPasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerMay 4, 2026 | globenewswire.comIs Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?May 3, 2026 | finance.yahoo.comPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)April 20, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN ...April 1, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityApril 1, 2026 | globenewswire.comPasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptFebruary 27, 2026 | seekingalpha.comPasithea Therapeutics Corp. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026February 17, 2026 | quiverquant.comQPasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 17, 2026 | globenewswire.comPasithea Therapeutics Shareholders Approve Expanded Equity AuthorizationJanuary 28, 2026 | tipranks.comPasithea Therapeutics Updates Clinical Trial Timelines for PAS-004 in Neurofibromatosis and Advanced CancerJanuary 13, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKTTA, ATYR, HYPD, and ATHE Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.98 -0.11 (-2.16%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$4.97 -0.01 (-0.20%) As of 07/17/2026 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.aTyr Pharma NASDAQ:ATYR$0.51 -0.01 (-1.14%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$0.51 0.00 (-0.20%) As of 07/17/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Hyperion DeFi NASDAQ:HYPD$2.74 -0.01 (-0.36%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$2.67 -0.07 (-2.55%) As of 07/17/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Pasithea Therapeutics NASDAQ:KTTA$0.45 -0.01 (-1.57%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$0.45 0.00 (0.00%) As of 07/17/2026 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/13- 07/17 The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
